Genotyping Market by Technology, Application & by Products - Global Forecast to 2020

Genotyping is used to study genetic variation in the genotypes of living organisms, including humans, animals, plants, and microorganisms. The genotyping market is mainly driven by technological advancements, increasing incidence of genetic diseases and awareness on personalized medicine, decreasing prices of DNA sequencing, growing importance of SNP genotyping in drug development, and the growing demand for genotyping of animal and plant livestock. However, ambiguity in the reimbursement for these products and a lack of well-trained lab technicians are drivers expected to restrain the growth of this market in the forecast period.
The market in this report is broadly segmented based on products and services, technology, applications, and end users. The market, by technology, is segmented into microarrays, capillary electrophoresis, polymerase chain reaction (PCR), sequencing, MALDI-TOF, allele specific oligonucleotide (ASO) probes, and others (in situ hybridization). Sequencing market is forecasted to grow at a highest CAGR 27.7% over the forecast period of 2015-2020, owing to its high speed, accuracy, flexibility, and increasing application areas.
Based on application, the market is segmented into pharmacogenomics, diagnostic research, animal genetics, agricultural biotechnology, and others (prenatal testing, parental testing, forensics, and microbial genotyping). The pharmacogenomics segment is expected to grow at a highest CAGR of 23.4% during the forecast period. The high growth in this segment is attributed to increasing use of genotyping in drug development process & to analyze the effects of drug.
The global genotyping market is expected to grow at a CAGR of 22.3% during the forecast period of 2015 to 2020 to reach $17.0 billion in 2020. Genotyping tests are increasingly being used in drug discovery and development process and to provide personalized therapy, factors that are driving market growth. In addition to this, heavy investments by key manufacturers to offer advanced and innovative products for wider applications are also propelling market growth.
Developed regions like North America and Europe will grow comparatively slower than emerging markets like Asia-Pacific and RoW (Latin America). Emerging countries are expected to record strong growth. Growth will be centered on countries like India, China, and Brazil owing to rising investments by public and private players in these countries, improving healthcare infrastructure, increase in the number of clinical research organizations and clinical trials in these countries, and the focus of leading players to capture growth opportunities in these markets.
Some prominent players in this market include Affymetrix, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies (U.S.), Beckman Coulter (U.S.), Sequenom, Inc. (U.S.), Roche (Switzerland), GE Healthcare (U.K.), and Fluidigm Corporation (U.S.). Various strategies such as collaborations, expansions, and new product launches helped these companies to maintain their market share and grow in this competitive market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms, and allow them to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use one or a combination of the below mentioned strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.

The report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by top players in the genotyping market. The report analyzes the genotyping market by products and applications.
 Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the genotyping market.
 Market Development: Comprehensive information about lucrative emerging markets by product & services, technology, application, end user, and region.
 Market Diversification: Exhaustive information about new products, geographies, recent developments, and investments in the genotyping market.
 Competitive Assessment: In-depth assessment of market shares, growth strategies, products, manufacturing capabilities, and SWOT analyses of leading players in the genotyping market.

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY & PRICING 17
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 19
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 22
2.1.2.3 Breakdown of primary interviews 22
2.2 MARKET SIZE ESTIMATION 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 MARKET SHARE ESTIMATION 25
2.5 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 GENOTYPING MARKET: GROWTH POTENTIAL 30
4.2 ASIA-PACIFIC GENOTYPING MARKET 31
4.3 GENOTYPING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 32
4.4 GEOGRAPHIC MIX: GENOTYPING MARKET, BY TECHNOLOGY 33
4.5 GENOTYPING MARKET, BY APPLICATION & GEOGRAPHY 34
4.6 GENOTYPING MARKET, BY GEOGRAPHY 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.2.1 GENOTYPING MARKET, BY PRODUCT 37
5.2.2 GENOTYPING MARKET, BY TECHNOLOGY 38
5.2.3 GENOTYPING MARKET, BY APPLICATION 38
5.2.4 GENOTYPING MARKET, BY END USER 38
5.3 MARKET DYNAMICS 39
5.3.1 DRIVERS 40
5.3.1.1 Technological advancements and decreasing prices of DNA sequencing 40
5.3.1.2 Increasing incidences of genetic diseases and rising awareness about personalized medicine 40
5.3.1.3 Growing importance of genotyping in the drug development process 40
5.3.1.4 Increasing demand for genome analysis in animal and plant livestock 41
5.3.2 RESTRAINTS 42
5.3.2.1 Dearth of trained resources 42
5.3.2.2 Significant initial investments 42
5.3.3 OPPORTUNITIES 43
5.3.3.1 Growing investments by leading players in emerging markets 43
5.3.3.2 Increasing application areas of genotyping 44
5.3.4 CHALLENGES 45
5.3.4.1 Increasing market consolidation 45
6 INDUSTRY INSIGHTS 46
6.1 INTRODUCTION 46
6.2 INDUSTRY TRENDS 46
6.2.1 INCREASING DEMAND FOR GENOTYPING & SEQUENCING SERVICES 46
6.3 PORTER’S FIVE FORCES ANALYSIS 47
6.3.1 THREAT OF NEW ENTRANTS 47
6.3.2 THREAT OF SUBSTITUTES 47
6.3.3 BARGAINING POWER OF SUPPLIERS 48
6.3.4 BARGAINING POWER OF BUYERS 48
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 48
6.4 STRATEGIC BENCHMARKING 49
6.4.1 PLAYERS ADOPTED NEW PRODUCT LAUNCHES AS A KEY STRATEGY TO INCREASE MARKET SHARES 49
7 GENOTYPING MARKET, BY PRODUCTS AND SERVICES 50
7.1 INTRODUCTION 51
7.2 REAGENTS & KITS 52
7.3 GENOTYPING SERVICES 53
7.4 INSTRUMENTS 54
7.4.1 SEQUENCERS & AMPLIFIERS 56
7.4.2 ANALYZERS 57
7.5 BIOINFORMATICS SOFTWARE 58
?
8 GENOTYPING MARKET, BY TECHNOLOGY 60
8.1 INTRODUCTION 61
8.2 POLYMERASE CHAIN REACTION (PCR) 62
8.2.1 REAL-TIME PCR 64
8.2.2 DIGITAL PCR 65
8.3 MICROARRAYS 66
8.4 SEQUENCING 67
8.4.1 NEXT-GENERATION SEQUENCING (NGS) 68
8.4.2 PYROSEQUENCING 69
8.4.3 SANGER SEQUENCING 70
8.5 CAPILLARY ELECTROPHORESIS 71
8.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM (AFLP) 73
8.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 74
8.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM (SSCP) 75
8.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT (MALDI-TOF) 76
8.7 OTHERS 77
9 GENOTYPING MARKET, BY APPLICATION 78
9.1 INTRODUCTION 79
9.2 PHARMACOGENOMICS 80
9.3 DIAGNOSTICS RESEARCH 81
9.4 AGRICULTURAL BIOTECHNOLOGY 82
9.5 ANIMAL GENETICS 83
9.6 OTHERS 84
10 GENOTYPING MARKET, BY END USER 86
10.1 INTRODUCTION 87
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 88
10.3 DIAGNOSTIC & RESEARCH LABORATORIES 89
10.4 ACADEMIC INSTITUTES 90
11 GENOTYPING MARKET, BY REGION 92
11.1 INTRODUCTION 93
11.2 NORTH AMERICA 95
11.2.1 U.S. 97
11.2.2 CANADA 99
11.3 EUROPE 101
11.3.1 GERMANY 103
11.3.2 U.K. 105
11.3.3 FRANCE 107
11.3.4 ITALY 109
11.3.5 SPAIN 111
11.3.6 REST OF EUROPE (ROE) 113
11.4 ASIA-PACIFIC 115
11.4.1 JAPAN 118
11.4.2 CHINA 120
11.4.3 INDIA 123
11.4.4 REST OF ASIA-PACIFIC 125
11.5 REST OF THE WORLD (ROW) 127
11.5.1 LATIN AMERICA 129
11.5.2 MIDDLE EAST AND AFRICA 131
12 COMPETITIVE LANDSCAPE 134
12.1 OVERVIEW 134
12.2 MARKET SHARE ANALYSIS (2014) 135
12.3 COMPETITIVE SITUATION AND TRENDS 136
12.3.1 NEW PRODUCT LAUNCHES 136
12.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 137
12.3.3 MERGERS AND ACQUISITIONS 138
12.3.4 OTHER DEVELOPMENTS 139
13 COMPANY PROFILES 140
13.1 AFFYMETRIX, INC. 141
13.1.1 BUSINESS OVERVIEW 141
13.1.2 PRODUCT PORTFOLIO 142
13.1.3 KEY STRATEGY 143
13.1.4 RECENT DEVELOPMENTS 143
13.2 ILLUMINA, INC. 145
13.2.1 BUSINESS OVERVIEW 145
13.2.2 PRODUCT PORTFOLIO 146
13.2.3 KEY STRATEGY 146
13.2.4 RECENT DEVELOPMENTS 147
13.3 QIAGEN N.V. 148
13.3.1 BUSINESS OVERVIEW 148
13.3.2 PRODUCT PORTFOLIO 149
13.3.3 KEY STRATEGY 151
13.3.4 RECENT DEVELOPMENTS 151
13.4 AGILENT TECHNOLOGIES, INC. 152
13.4.1 BUSINESS OVERVIEW 152
13.4.2 PRODUCT PORTFOLIO 153
13.4.3 KEY STRATEGY 153
13.4.4 RECENT DEVELOPMENTS 154
?
13.5 FLUIDIGM CORPORATION 155
13.5.1 BUSINESS OVERVIEW 155
13.5.2 PRODUCT PORTFOLIO 155
13.5.3 KEY STRATEGY 156
13.5.4 RECENT DEVELOPMENTS 156
13.6 LIFE TECHNOLOGIES CORPORATION 157
13.6.1 BUSINESS OVERVIEW 157
13.6.2 PRODUCT PORTFOLIO 158
13.6.3 KEY STRATEGY 162
13.6.4 RECENT DEVELOPMENTS 163
13.7 ROCHE DIAGNOSTICS LIMITED 164
13.7.1 BUSINESS OVERVIEW 164
13.7.2 PRODUCT PORTFOLIO 165
13.7.3 KEY STRATEGY 165
13.7.4 RECENT DEVELOPMENTS 165
13.8 GE HEALTHCARE 166
13.8.1 BUSINESS OVERVIEW 166
13.8.2 PRODUCT PORTFOLIO 167
13.8.3 KEY STRATEGY 167
13.8.4 RECENT DEVELOPMENTS 167
13.9 BECKMAN COULTER, INC. 168
13.9.1 BUSINESS OVERVIEW 168
13.9.2 PRODUCT PORTFOLIO 168
13.9.3 KEY STRATEGY 169
13.9.4 RECENT DEVELOPMENTS 169
13.10 SEQUENOM, INC. 170
13.10.1 BUSINESS OVERVIEW 170
13.10.2 PRODUCT PORTFOLIO 170
13.10.3 KEY STRATEGY 170
13.10.4 RECENT DEVELOPMENTS 171
14 APPENDIX 172
14.1 INSIGHTS OF INDUSTRY EXPERTS 172
14.2 OTHER DEVELOPMENTS 173
14.3 DISCUSSION GUIDE 176
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 180
14.5 AVAILABLE CUSTOMIZATIONS 182
14.6 RELATED REPORTS 182